NIDB 3001
Alternative Names: NI-3001; NIDB-3001Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Light Chain Bioscience
- Class Antibacterials; Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Gram-negative-infections in Switzerland (Parenteral)
- 30 Nov 2020 Discoveric Bio collaborates with Light Chain Bioscience to develop multispecific antibodies for multi-drug resistant Gram-negative infections
- 30 Nov 2020 Early research in Gram-negative infections in Switzerland (Parenteral)